Outlook Therapeutics (OTLK) CFO Kenyon Acquires 101,010 Shares

What Happened

• Lawrence A. Kenyon, Chief Financial Officer of Outlook Therapeutics (OTLK), acquired 101,010 shares of common stock and accompanying warrants to purchase 101,010 shares in the company's underwritten public offering on August 14, 2026. The combined public offering price was $0.99 per share plus accompanying warrant, for a total cash outlay of about $99,999.90 (≈ $100k). This was a purchase (acquisition), not a sale.

Key Details

• Transaction date: August 14, 2026 (reported on the same date).
• Transaction type: Purchase in an underwritten public offering (Form 4 code P); derivative entry reflects the warrants.
• Quantity and price: 101,010 common shares + warrants for 101,010 shares; $0.99 combined price per share + warrant; total ≈ $100,000.
• Warrants: Exercisable immediately upon issuance and expire five years later (August 14, 2031) (see footnote).
• Shares owned after transaction: Not specified in the provided filing.
• Filing timeliness: The Form 4 was filed on August 14, 2026 (same day as the reported transaction), so the report appears timely.

Context

• The purchase came via the company’s underwritten offering, not an open-market trade. The derivative entry represents warrants issued alongside the shares; these give the holder the right (but not the obligation) to buy additional shares under terms stated in the offering (warrant exercise price and other terms are in the offering documents, not the Form 4). Purchases by insiders can be viewed as more informative than sales, but the filing itself does not state the insider’s motivation.